Department of Nursing, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, R.O.C.
Department of Nursing, Tzu-Chi University, Hualien, Taiwan, R.O.C.
In Vivo. 2023 Mar-Apr;37(2):948-954. doi: 10.21873/invivo.13167.
BACKGROUND/AIM: Infection is a common cause of morbidity and mortality in patients treated for diffuse large B-cell lymphoma (DLBCL). However, there is limited information on the impact and risk factors for infection among patients receiving rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP).
A retrospective study evaluating patients with DLBCL receiving R-CHOP and R-COP between 2004 and 2021 was conducted at a medical center. Hospital patients' records for the five-item modified frailty index (mFI-5), sarcopenia, blood-based inflammatory markers, and clinical outcomes were statistically analyzed.
Patients with frailty, sarcopenia, and high neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of infections. The revised International Prognostic Index poor-risk group, high NLR, infections, and treatment modality were risk factors for shorter progression-free and overall survival.
Pre-treatment high NLR was a predictor of infection and survival outcome in DLBCL patients.
背景/目的：感染是接受弥漫性大 B 细胞淋巴瘤（DLBCL）治疗患者发病率和死亡率的常见原因。然而，对于接受利妥昔单抗、环磷酰胺、长春新碱、多柔比星和泼尼松（R-CHOP）治疗的患者，有关感染的影响和危险因素的信息有限。
在一家医疗中心进行了一项回顾性研究，评估了 2004 年至 2021 年间接受 R-CHOP 和 R-COP 治疗的 DLBCL 患者。对五项改良虚弱指数（mFI-5）、肌肉减少症、基于血液的炎症标志物和临床结果的住院患者记录进行了统计学分析。
虚弱、肌肉减少症和高中性粒细胞与淋巴细胞比值（NLR）的患者感染风险更高。修订后的国际预后指数不良风险组、高 NLR、感染和治疗方式是无进展生存期和总生存期较短的危险因素。
治疗前高 NLR 是 DLBCL 患者感染和生存结果的预测因素。
